Overview

A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if participants with platinum-refractory or platinum-resistant advanced ovarian cancer have a better outcome when treated with Olaratumab (IMC-3G3) in combination with Liposomal Doxorubicin than when treated with Liposomal Doxorubicin alone.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Doxorubicin
Liposomal doxorubicin
Olaratumab